NIH scientists used human cerebral organoid to test drug for deadly brain disease
On Mar. 9, 2021, the NIH announced that approximately two years after establishing a human cerebral organoid system…
Agilent completed CE-IVD registration of qRT-PCR In vitro diagnostic kit for SARS-CoV-2 RNA detection
On Mar. 9, 2021, Agilent Technologies announced the launch of a real-time reverse transcription (qRT) PCR-based diagnostic kit…
NanoViricides pan-coronavirus COVID-19 drug candidates highly effective in pre-clinical animal atudies
On Mar. 9, 2021, NanoViricides announced that NV-CoV-2 and NV-CoV-2-R were found to be highly effective against a…
Oragenics announced Material Transfer Agreement with Biodextris for mucosal adjuvant for intranasal COVID-19 vaccine
On Mar. 9, 2021, Oragenics announced it had entered into a material transfer agreement with Biodextris for the…
VBI Vaccines announced enrollment in adaptive phase 1/2 study of prophylactic COVID-19 vaccine candidate
On Mar. 9, 2021, VBI Vaccines announced the initiation of enrollment of its Phase 1/2 clinical study of…
ImmunityBio and NantKwest began dosing participants in global trials for novel COVID-19 vaccine
On Mar. 8, 2021, ImmunityBio and NantKwest announced that the first cohorts of their South Africa and U.S….
AIM ImmunoTech announced first healthy subjects dosed in phase 1 intranasal Ampligen clinical study
On Mar. 8, 2021, AIM ImmunoTech announced that it had dosed the first healthy subjects in its Phase…
FDA issued authorization for first molecular non-prescription, at-home test
On Mar. 5, 2021, the U.S. Food and Drug Administration issued an emergency use authorization (EUA) for the…
FDA authorized Cue Health’s COVID-19 test for at-mome and Over The Counter Use
On Mar. 5, 2021, Cue Health announced it had received Emergency Use Authorization (EUA) from the U.S. Food…
Abivax stopped phase 2b/3 miR-AGE Covid-19 clinical trial due to lack of efficacy
On Mar. 5, 2021, Abivax announced tthat it was halting the miR-AGE phase 2b/3 clinical trial in high-risk…
Ridgeback Biotherapeutics and Merck announced preliminary findings from phase 2a trial of investigational COVID-19 therapeutic
On Mar. 5, 2021, Merck and Ridgeback Biotherapeutics, announced preliminary results from Ridgebackﾒs Phase 2a randomized, double-blind, placebo-controlled…
CureVac and Novartis signed initial agreement on manufacturing of COVID-19 vaccine candidate, CVnCoV
On Mar. 4, 2021, CureVac and Novartis announced an initial agreement for the manufacturing of CureVacﾒs COVID-19 vaccine…
NIH-sponsored ACTIV-3 clinical trial closed enrollment into two sub-studies
On Mar. 4, 2021, the NIH announced that the ACTIV-3 clinical trial evaluating the safety and efficacy of…
New evidence COVID-19 antibodies, vaccines less effective against variants
On Mar. 4, 2021, researchers at the University School of Medicine in St. Louis announced that three new,…
Soligenix announced positive progress in pre-clinical development of its COVID-19 vaccine
On Mar. 4, 2021, Soligenix announced publication of pre-clinical immunogenicity studies for CiVaxﾙ (heat stable COVID-19 vaccine program)…
Men, older adults and smokers more prone to infection by SARS-CoV-2
On Mar. 3, 2021, TGen, an affiliate of City of Hope announced that an in-depth analysis of the…
MediciNova announced it had discontinued development of a SARS-CoV-2 vaccine for COVID-19
On Mar. 2, 2021, MediciNova announced it that given the COVID-19 vaccines currently in use and other vaccines…
NanoViricides pan-coronavirus COVID-19 drug candidates highly effective in pre-clinical animal atudies
On Mar. 2, 2021, NanoViricides reported that NV-CoV-2 and NV-CoV-2-R were found to be highly effective in comparison…
Innovation Pharma announced publication in Journal Viruses on the anti-SARS-CoV-2 properties of brilacidin
On Mar. 2, 2021, Innovation Pharmaceuticals reported that eight sites were participating in the Companyﾒs international Phase 2…
Cerecor announced postitive data in phase 2 clinical trial in patients hospitalized with COVID-19 ARDS
On Mar. 2, 2021, Cerecor announced final efficacy data including 60-day mortality from their completed US-based, multi-center (10…
COVAX published first round of allocations
On Mar. 2, 2021, The Coalition for Epidemic Preparedness Innovations (CEPI), Gavi, the Vaccine Alliance and the WHO,…
NIH halted trial of COVID-19 convalescent plasma in emergency department patients with mild symptoms
On Mar. 2, 2021, the NIH halted a clinical trial evaluating the safety and effectiveness of COVID-19 convalescent…
NIH launched effort to understand MIS-C, range of SARS-CoV-2 effects on children
On Mar. 2, 2021, the NIH announced that it had launched a research effort to understand how SARS-CoV-2,…
Biden administration announced collaboration between Merck and Johnson & Johnson to expand production of COVID-19 vaccines
On Mar. 2, 2021, the Biden Administration has helped forge a historic manufacturing collaboration between two of the…
CDC’s ACIP issued interim recommendation for use of Ebola vaccine
On Mar. 2, 2021, the Advisory Committee on Immunization Practices (ACIP) recommended preexposure vaccination with Merck’s Ervebo was…
CDC’s ACIP issued interim recommendation for use of Janssen COVID-19 vaccine
On Feb. 28, 2021, after a transparent evidence-based review of all available data, the Advisory Committee on Immunization…
CDC Advisory Committee recommended single-shot COVID-19 vaccine for adults 18 and older in US
On Feb. 28, 2021, Johnson & Johnson announced that the U.S. Centers for Disease Control and Preventionﾒs (CDC)…
Johnson & Johnson single-shot COVID-19 vaccine authorized by US FDA for Emergency Use
On Feb. 27, 2021, Johnson & Johnson announced that the U.S. Food and Drug Administration (FDA) had issued…
Roche SARS-CoV-2 rapid rntigen test received special approval for at-home patient self-testing in Germany
On Feb. 26, 2021, Roche announced it had been granted special approval by the German Federal Institute for…
Innovation Pharma provided study details for phase 2 clinical trial of Brilacidin in hospitalized COVID-19 patients
On Feb. 26, 2021, Innovation Pharmaceuticals announced that after an interim review, by an independent Data Monitoring Committee…